top of page
Biosciences
Offspring
Insights & Updates
Four Reasons Antibody Programs Fail Before They Reach Patients
The most successful translational strategies increasingly focus on generating human-relevant evidence earlier, when development teams still have the opportunity to refine candidate selection, optimize trial design, and reduce uncertainty before major investments are made.
Featured
Search
Beyond the Checklist: Strategic TMAs for Definitive Tissue Cross-Reactivity
Executed strategically, using a specifically curated Tissue Microarray (TMA), TCR studies provide a rich dataset that provides "Deep Insights" into novel therapeutic antibodies, their comparative performance, and their associated risk in human patient trials.
evadanielson55
May 264 min read
The One-Shot Gamble: Why Most IND-Enabling Programs Enter GLP-TCR With Too Little Data — and How to Change That
Offspring Biosciences | Tissue Insights™ | Preclinical Safety: Enhancing Drug Development There is a critical decision point in almost every therapeutic antibody program that deserves more strategic attention. This moment occurs just before the formal GLP Tissue Cross-Reactivity (TCR) study. This study is the FDA and EMA-mandated IHC screen of the drug candidate across a defined panel of normal human organ tissues. Without it, an IND cannot be filed. Most program teams treat
evadanielson55
May 124 min read
bottom of page